Quantum BioPharma has closed a debt settlement by issuing 30,948 Class B subordinate voting shares worth CAD$123,487.43 to its creditors. The shares were priced at CAD$3.99 each, based on the previous trading day's closing price on the Canadian Securities Exchange. This move clears the company's outstanding debt to arm’s length creditors and insiders. Quantum BioPharma continues to focus on developing treatments for neurodegenerative and metabolic disorders, with ongoing projects including its lead compound Lucid-MS for multiple sclerosis.
Halper Sadeh LLC is investigating whether the sales and mergers involving Utz Brands, BioLife Solutions, and Northrim BanCorp provide fair financial terms to their shareholders. The firm suspects insiders might gain benefits not available to ordinary...
Mesoblast announced $36 million in net revenue for Q4 and $115 million for the first full year following FDA approval of its Ryoncil therapy, used to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The company is expa...
Fortuna Mining Corp. has approved a $109 million expansion of its Séguéla Gold Mine in Côte d’Ivoire, increasing processing capacity by 30% from 1.75 to 2.3 million tonnes per annum and improving gold recovery to 94.5%. This expansion includes upgrad...
BeOne Medicines is evolving from relying on its BRUKINSA drug to becoming an integrated hematology and oncology company with multiple growth drivers. In Q1 2026, the company reported a 35.5% increase in revenue, expanding profit margins, and rising p...
BNB Chain has led all blockchain networks with $19 billion in weekly decentralized exchange (DEX) volume, driven mainly by PancakeSwap. This surge highlights its low fees and high throughput advantages, attracting retail traders and memecoin fans. Wh...
